The innovative biotech company located in Vienna.

AVIR Green Hills Biotechnology commences deltaFLU Stage II study By Starting the Phase II Study for deltaFLU, AVIR Green Hills AG has Accomplished another Milestone in the Development of the Novel Influenza Vaccine. Completion of the Clinical Phase II Research is Envisaged for Planting season 2010 The Positive Results Obtained in the last Clinical Phase I Research will be Published in the Renowned Journal of Infectious Diseases on 15 January 2010 AVIR Green Hills Biotechnology, the innovative biotech company located in Vienna, has started the brand new Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU.Cholera deaths and infections keep rising in Haiti after the disease suddenly reemerged in the earthquake aftermath; meanwhile, aid dwindles and health officials scramble for assets. Related StoriesCombatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr ChakravarthyAnalyzing potential TB vaccineDeaths from avoidable risk elements: an interview with Dr Ali Mokdad, IHMEChernobyl, Japan and Beyond: Radiation and Health: New perspectives on short-term responses and long-term health effects of radiation emergencies as nuclear security issues surge in the wake of the reactor meltdown in Japan.